Paola Dimartino

Paola Dimartino

Auto-generated profile, based on publicly available information

Paola Dimartino

Department of Molecular Medicine, University of Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CGChiara Giovenino
Chiara Giovenino
STSlavica Trajkova
Slavica Trajkova
Lisa PavinatoLisa Pavinato
Lisa Pavinato
SCSimona Cardaropoli
Simona Cardaropoli
VPVerdiana Pullano
Verdiana Pullano
ABAlfredo Brusco
Alfredo Brusco
Despite major advances in genome technology and analysis, >50% of patients with a neurodevelopmental disorder (NDD) remain undiagnosed after extensive evaluation. A point in case is our clinically heterogeneous cohort of NDD patients that remained undiagnosed after FRAXA testing, chromosomal microarray analysis and trio exome sequencing (ES). In this study, we explored the frequency of non-random X chromosome inactivation (XCI) in the mothers of male patients and affected females, the rationale being that skewed XCI might be masking previously discarded genetic variants found on the X chromosome. A multiplex fluorescent PCR-based assay was used to analyse the pattern of XCI after digestion with HhaI methylation-sensitive restriction enzyme. In families with skewed XCI, we re-evaluated trio-based ES and identified pathogenic variants and a deletion on the X chromosome. Linkage analysis and RT-PCR were used to further study the inactive X chromosome allele, and Xdrop long-DNA technology was used to define chromosome deletion boundaries. We found skewed XCI (>90%) in 16/186 (8.6%) mothers of NDD males and in 12/90 (13.3%) NDD females, far beyond the expected rate of XCI in the normal population (3.6%, OR = 4.10; OR = 2.51). By re-analyzing ES and clinical data, we solved 7/28 cases (25%) with skewed XCI, identifying variants in KDM5C, PDZD4, PHF6, TAF1, OTUD5 and ZMYM3, and a deletion in ATRX. We conclude that XCI profiling is a simple assay that targets a subgroup of patients that can benefit from re-evaluation of X-linked variants, thus improving the diagnostic yield in NDD patients and identifying new X-linked disorders.

8 July 2026 in Human Genetics
Verified
Journal Article
Open access
PDF file
Simona CardaropoliSimona Cardaropoli
Simona Cardaropoli
Lisa PavinatoLisa Pavinato
Lisa Pavinato
STSlavica Trajkova
Slavica Trajkova
DCDiana Carli
Diana Carli
VPVerdiana Pullano
Verdiana Pullano
GFGiovanni Battista Ferrero
Giovanni Battista Ferrero
Exome sequencing (ES) has become a primary tool for diagnosing neurodevelopmental disorders (NDDs), yet the interpretation of genetic variants in large, heterogeneous cohorts presents significant challenges that automated pipelines often fail to resolve. This study showcases the complexities and novel findings derived from a decade-long analysis of 419 Italian NDD patient-parent trios. While ES established a molecular diagnosis in 36.5% of cases (53.8% in syndromic presentations), our investigation moves beyond diagnostic yield to highlight the critical value of manual curation integrated with deep phenotyping. We demonstrate how this rigorous approach uncovers complex disease mechanisms, revealing that variants initially misclassified as missense or stop-gain are, in fact, pathogenic splicing defects confirmed by functional analysis. Furthermore, we resolve the paradox of pathogenic truncating PPM1D variants in control databases by demonstrating their somatic mosaic nature, a crucial insight for population data interpretation. Our work also refines gene-disease correlations by challenging the established role of MID2 in NDDs, providing further evidence for DSCAM as a high-confidence risk gene, and expanding the known phenotypic spectrum of disorders, such as a novel GNAI2 -related syndrome lacking expected immune dysfunction. This study underscores that navigating the complexities of large NDD cohorts requires a detailed, expert-driven approach to not only enhance diagnostic yield but also to advance our fundamental understanding of rare disease genetics.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
STSlavica Trajkova
Slavica Trajkova
Simona CardaropoliSimona Cardaropoli
Simona Cardaropoli
PDPaola Dimartino
Paola Dimartino
Lisa PavinatoLisa Pavinato
Lisa Pavinato
SRSerena Rizzo
Serena Rizzo
ABAlfredo Brusco
Alfredo Brusco
Neurodevelopmental disorders (NDDs) are among the most genetically complex human conditions, yet even in the era of routine exome sequencing (ES), a large fraction of patients remains without a molecular diagnosis. Here, we analyzed 203 unrelated families from NeuroWES‐Macedonia, the first national genomic initiative in North Macedonia, using a fully integrated diagnostic strategy that combined trio‐based ES, copy number variant (CNV) analysis, RNA studies, and DNA methylation (episignature) profiling. Rather than focusing solely on diagnostic yield, we systematically examined recurrent interpretative failure modes that lead to missed, delayed, or incomplete diagnoses in routine clinical genomics. Likely pathogenic or pathogenic variants were identified in 29.6% (60/203) of probands, with diagnostic yield rising to 62.3% (38/61) in syndromic NDDs. However, many of the most instructive cases lay beyond conventional Mendelian expectations. We uncovered cryptic splicing defects evade in silico prediction, low‐level parental and proband mosaicism, multilocus genomic disease, and inherited pathogenic variants concealed by subtle or unrecognized parental phenotypes. Epigenomic profiling proved particularly powerful in resolving cases involving chromosomal abnormalities, mosaic aneuploidies, and overlapping syndromes, allowing us to disentangle primary from secondary molecular drivers. Beyond improving diagnostic understanding, analysis of this cohort expanded the mutational and phenotypic spectra of known NDD genes and yielded novel candidate disease genes, several of which were independently validated through international data sharing. Importantly, multiple cases demonstrated how rigid inheritance assumptions, reliance on de novo filtering, and compartmentalized analysis of SNVs and CNVs can actively obscure true disease mechanisms—even when high‐quality sequencing data are available. Together, our findings show that the persistent diagnostic gap in NDDs is driven not only by missing genes but also by systematic blind spots in variant interpretation. Integrating multiomic data with phenotype‐driven, flexible analytic frameworks is essential to unlock the full potential of genomic medicine in NDDs.

8 October 2026 in Genes
Verified
Journal Article
Open access
PDF file
EEEdoardo Errichiello
Edoardo Errichiello
PDPaola Dimartino
Paola Dimartino
Rare genetic diseases (RGDs) affect more than 300–400 million people worldwide